Organogenesis Shares Are Trading Higher After the Company Announced That Its Phase 3 Randomized Control Trial Evaluating the Safety and Efficacy of ReNu Achieved Its Primary Endpoint.
Organogenesis Shares Are Trading Higher After the Company Announced That Its Phase 3 Randomized Control Trial Evaluating the Safety and Efficacy of ReNu Achieved Its Primary Endpoint.
Organogenesis宣佈其評估ReNU安全性和有效性的3期隨機對照試驗已達到其主要終點後，該公司股價走高。
Organogenesis Shares Are Trading Higher After the Company Announced That Its Phase 3 Randomized Control Trial Evaluating the Safety and Efficacy of ReNu Achieved Its Primary Endpoint.
Organogenesis宣佈其評估ReNU安全性和有效性的3期隨機對照試驗已達到其主要終點後，該公司股價走高。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。